Cardarine (GW-501516) is grouped in the category of SARMS, however in structure and definition, it is a PPAR modulator. As a PPAR modulator, it activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue. GW-501516 possesses abilities to reverse metabolism problems by stimulating fatty acid oxidation. It is considered a strong treatment for obesity and other related conditions.
Several research studies have been conducted on rats with Cardarine (GW-501516) implementation. GW is a selective agonist, or activator, of the PPAR receptor. The binding of GW-501516 to PPAR recruits the co activator PGC-1a. The PPAR/co activator complex then up regulates the expression of proteins involved in energy expenditure.
GW-501516 has also show to increase fatty acid metabolism in skeletal muscle and protect against obesity caused from diet. Testing conducted on obese rhesus monkeys proved GW increased HDL (good cholesterol) and lowered VLDL (bad cholesterol). GW was originally intended to be created as a treatment for cholesterol problems, which it has shown to possess a high rate of efficacy in doing.